Biotricity, a California-based healthcare technology company, has received FDA clearance for its new three-lead electrocardiogram (ECG) and arrhythmia monitoring solution.
The Biotres Cardiac Monitoring Device was built to help monitor the cardiac health of low-risk patients. It includes Bluetooth connectivity, a rechargeable battery and an adjustable design that can be updated in the future as additional features are finalized.
“Cardiac disease remains a chronic issue, requiring persistent intervention, monitoring and management and we believe Biotres may provide a critical tool for improving patient lives and reducing costs,” Waqaas Al-Siddiq, PhD, Biotricity founder and CEO, said in a prepared statement.
Al-Siddiq also pointed to the company’s recent financing success, saying that Biotricity now has a great opportunity to expand its commercialization efforts.
The Biotres Cardiac Monitoring Device is scheduled to be available for purchase on April 1.
Michael has more than 16 years of experience as a professional writer and editor. He has written at length about cardiology, radiology, artificial intelligence and other key healthcare topics.